FDA Should Take Action on Unfeasible Guidances to Help Boost Stagnant US Antibiotics Market
With a diminishing antibiotics pipeline and one of the primary market needs lying in the availability of effective antibiotics for hospital-acquired pneumonia, FDA needs to take serious action to allow for the introduction of novel innovations in the US market, says an analyst with research and consulting firm GlobalData.
According to Dr Haylyn Wong, GlobalData’s Healthcare Analyst for Cardiovascular and Metabolic Disorders, FDA possesses a long history of having what many consider “unfeasible guidances” for the design of antibiotic clinical trials. As a result, the organisation is now trailing behind the European Medicines Agency (EMA) after the latter released a new addendum to its guideline on the evaluation of medicinal products indicated for treating bacterial infections.
Dr Wong says: “With a strong focus on facilitating the development of antibacterial agents targeted against multidrug-resistant (MDR) pathogens, EMA’s expanded guidance continues to highlight its efforts in developing new antibacterial guidelines that prioritise feasibility.
“Following its release, a trend has now emerged whereby drug companies are encouraged to develop novel antibiotics for the European (EU) market before attempting to gain regulatory approval in the US, which is a detriment to the US market.”
Basilea Pharmaceutica’s antibiotic, ceftobiprole, gained EU regulatory approval in October 2013, where it is now indicated for the treatment of both hospital- and community-acquired pneumonia. Although the company had attempted to gain regulatory approval in the US, its initial rejection by FDA and unsuccessful renegotiations means it is unlikely to continue pushing for this approval.
GlobalData now expects that other drug developers will follow Basilea Pharmaceutica’s example and attempt to register in Europe before approaching the US regulator.
Dr Wong continues: “Despite currently being on the back foot, FDA has made some attempt at catching up to the EMA’s advances in improving the regulatory pathway. Most notably, it published a draft guidance in July, entitled Antibacterial Therapies for Patients with Unmet Medical Need for the Treatment of Serious Bacterial Diseases. This called upon sponsors to submit plans and designs for clinical trials.
“However, a stagnant antibacterial pipeline means that FDA still has a lot of hard work ahead, if it wants to ensure that the latest novel antibiotic innovations are not just made available to the EU,” the analyst concludes.
Related News
-
News Pharmaceutical industry supports COP28 health stance in joint statement
As COP28 takes place over this week in Dubai, UAE, several bodies in the pharmaceutical and health industries have come together to announce support of key movements in sustainability in the sector, and to recognise sustainability as a health issue.&nb... -
News Biden backs Cold-War measures to shore-up medical supply chains
In a recent strategy to combat rising inflation and the cost of living crisis, President Joe Biden has invoked a Cold War-era act to increase investment in a selection of medicines and supplies. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Novartis agrees for copies to be made of cancer drug to reach poorer countries
Novartis signs agreement with MPP to have generics of it's leukemia drug made so that it can be more easily distributed to the world's poorer countries. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute. -
News New WHO health emergency guidelines expect full transparency from Big Pharma
The WHO are proposing a new set of pandemic guidelines to set out how future global health crises should be handled.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance